LEADER 01513nam  2200469   450 
001 9910707230803321
005 20160624083931.0
035   $a(CKB)5470000002463202
035   $a(OCoLC)952174823
035   $a(OCoLC)995470000002463202
035   $a(EXLCZ)995470000002463202
100   $a20160624d2004      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aMedicare reimbursement for lupron
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2004.
215   $a1 online resource (ii, 9 pages) $cillustrations
300   $aTitle from title screen (viewed June 23, 2016).
300   $a"January 2004."
300   $a"OEI-03-03-00250."
517 1 $aMedicare reimbursement for lupron
606   $aMedicare
606   $aProstate$xCancer$xTreatment
606   $aSymptoms$xTreatment$zUnited States
606   $aPharmaceutical policy$zUnited States
606   $aPharmaceutical services insurance$zUnited States
606   $aDrugs$xPrices$zUnited States
615  0$aMedicare.
615  0$aProstate$xCancer$xTreatment.
615  0$aSymptoms$xTreatment
615  0$aPharmaceutical policy
615  0$aPharmaceutical services insurance
615  0$aDrugs$xPrices
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707230803321
996   $aMedicare reimbursement for lupron$93310626
997   $aUNINA